Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review
Penile squamous cell carcinoma (PSCC) bears poor prognosis due to its rarity and limited treatment options, especially after failure of standard treatments. Effective therapeutic options were desperately needed. We report a recurrent metastatic PSCC patient with positive programmed death ligand 1 (P...
Gespeichert in:
Veröffentlicht in: | OncoTargets and therapy 2020-01, Vol.13, p.3319-3324 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3324 |
---|---|
container_issue | |
container_start_page | 3319 |
container_title | OncoTargets and therapy |
container_volume | 13 |
creator | Su, Xiangyu Zhang, Jing Fu, Chenchun Xiao, Mingzhe Wang, Cailian |
description | Penile squamous cell carcinoma (PSCC) bears poor prognosis due to its rarity and limited treatment options, especially after failure of standard treatments. Effective therapeutic options were desperately needed.
We report a recurrent metastatic PSCC patient with positive programmed death ligand 1 (PD-L1) expression (≥10%) and tumor mutation burden (TMB) of 8.87 (Muts/Mb) who obtained significant response to immunotherapy, with progression-free survival (PFS) exceeding 10 months.
This is the first case presenting remarkable response to immunotherapy in a Chinese PSCC patient. The remarkable response might be associated with PD-L1 expression, indicating that PD-L1 expression could be a promising biomarker for immunotherapy in PSCC. TMB ranking may also contribute to patient selection. However, large clinical trials are needed to validate these notions. |
doi_str_mv | 10.2147/OTT.S231258 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7183339</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32368090</sourcerecordid><originalsourceid>FETCH-LOGICAL-c348t-ec3bf1c07bc43a0501150bd46bd42dc7bb7a2ccfc5a7add190e261d1577a450b3</originalsourceid><addsrcrecordid>eNpVUctOwzAQtBCIR-HEHfmOAnacxCkHJCivSkWN2nKOHGfTGjVOZDsFfoZvxVVLBYfVrmZmZ7UahM4puQppxK_Hs9nVNGQ0jNM9dEwpT4Okz8j-n_kInVj7TkiSpGF0iI5YyJKU9Mkx-p6A7IwB7fArOGGdcEriDLRaAh4ILcHgzGNrwYdyC5w1Vjm1Apw9BCOKHz9bA9aqRuNx4YTSUOKpmmtVKSn8zj1oqJTDlWlqPKzrTjduAUa0Xzf4zh-wgCfQNsZhoUs8Us5zrjNrdKXg4xQdVGJp4Wzbe-jt6XE2eAlG4-fh4G4USBalLgDJiopKwgsZMUFiQmlMijJKfIWl5EXBRShlJWPBRVnSPoEwoSWNOReRV7Ieut34tl1RQyn9u0Ys89aoWpivvBEq_89otcjnzSrnNGWM9b3B5cZAmsZaA9Vul5J8HVPuY8q3MXn1xd9zO-1vLuwHY7OSgQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review</title><source>Taylor & Francis Open Access</source><source>DOVE Medical Press Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Su, Xiangyu ; Zhang, Jing ; Fu, Chenchun ; Xiao, Mingzhe ; Wang, Cailian</creator><creatorcontrib>Su, Xiangyu ; Zhang, Jing ; Fu, Chenchun ; Xiao, Mingzhe ; Wang, Cailian</creatorcontrib><description>Penile squamous cell carcinoma (PSCC) bears poor prognosis due to its rarity and limited treatment options, especially after failure of standard treatments. Effective therapeutic options were desperately needed.
We report a recurrent metastatic PSCC patient with positive programmed death ligand 1 (PD-L1) expression (≥10%) and tumor mutation burden (TMB) of 8.87 (Muts/Mb) who obtained significant response to immunotherapy, with progression-free survival (PFS) exceeding 10 months.
This is the first case presenting remarkable response to immunotherapy in a Chinese PSCC patient. The remarkable response might be associated with PD-L1 expression, indicating that PD-L1 expression could be a promising biomarker for immunotherapy in PSCC. TMB ranking may also contribute to patient selection. However, large clinical trials are needed to validate these notions.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S231258</identifier><identifier>PMID: 32368090</identifier><language>eng</language><publisher>New Zealand: Dove</publisher><subject>Case Report</subject><ispartof>OncoTargets and therapy, 2020-01, Vol.13, p.3319-3324</ispartof><rights>2020 Su et al.</rights><rights>2020 Su et al. 2020 Su et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c348t-ec3bf1c07bc43a0501150bd46bd42dc7bb7a2ccfc5a7add190e261d1577a450b3</citedby><cites>FETCH-LOGICAL-c348t-ec3bf1c07bc43a0501150bd46bd42dc7bb7a2ccfc5a7add190e261d1577a450b3</cites><orcidid>0000-0001-6027-3543</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183339/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183339/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,3860,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32368090$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Su, Xiangyu</creatorcontrib><creatorcontrib>Zhang, Jing</creatorcontrib><creatorcontrib>Fu, Chenchun</creatorcontrib><creatorcontrib>Xiao, Mingzhe</creatorcontrib><creatorcontrib>Wang, Cailian</creatorcontrib><title>Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>Penile squamous cell carcinoma (PSCC) bears poor prognosis due to its rarity and limited treatment options, especially after failure of standard treatments. Effective therapeutic options were desperately needed.
We report a recurrent metastatic PSCC patient with positive programmed death ligand 1 (PD-L1) expression (≥10%) and tumor mutation burden (TMB) of 8.87 (Muts/Mb) who obtained significant response to immunotherapy, with progression-free survival (PFS) exceeding 10 months.
This is the first case presenting remarkable response to immunotherapy in a Chinese PSCC patient. The remarkable response might be associated with PD-L1 expression, indicating that PD-L1 expression could be a promising biomarker for immunotherapy in PSCC. TMB ranking may also contribute to patient selection. However, large clinical trials are needed to validate these notions.</description><subject>Case Report</subject><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVUctOwzAQtBCIR-HEHfmOAnacxCkHJCivSkWN2nKOHGfTGjVOZDsFfoZvxVVLBYfVrmZmZ7UahM4puQppxK_Hs9nVNGQ0jNM9dEwpT4Okz8j-n_kInVj7TkiSpGF0iI5YyJKU9Mkx-p6A7IwB7fArOGGdcEriDLRaAh4ILcHgzGNrwYdyC5w1Vjm1Apw9BCOKHz9bA9aqRuNx4YTSUOKpmmtVKSn8zj1oqJTDlWlqPKzrTjduAUa0Xzf4zh-wgCfQNsZhoUs8Us5zrjNrdKXg4xQdVGJp4Wzbe-jt6XE2eAlG4-fh4G4USBalLgDJiopKwgsZMUFiQmlMijJKfIWl5EXBRShlJWPBRVnSPoEwoSWNOReRV7Ieut34tl1RQyn9u0Ys89aoWpivvBEq_89otcjnzSrnNGWM9b3B5cZAmsZaA9Vul5J8HVPuY8q3MXn1xd9zO-1vLuwHY7OSgQ</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Su, Xiangyu</creator><creator>Zhang, Jing</creator><creator>Fu, Chenchun</creator><creator>Xiao, Mingzhe</creator><creator>Wang, Cailian</creator><general>Dove</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6027-3543</orcidid></search><sort><creationdate>20200101</creationdate><title>Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review</title><author>Su, Xiangyu ; Zhang, Jing ; Fu, Chenchun ; Xiao, Mingzhe ; Wang, Cailian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c348t-ec3bf1c07bc43a0501150bd46bd42dc7bb7a2ccfc5a7add190e261d1577a450b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Case Report</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Su, Xiangyu</creatorcontrib><creatorcontrib>Zhang, Jing</creatorcontrib><creatorcontrib>Fu, Chenchun</creatorcontrib><creatorcontrib>Xiao, Mingzhe</creatorcontrib><creatorcontrib>Wang, Cailian</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Su, Xiangyu</au><au>Zhang, Jing</au><au>Fu, Chenchun</au><au>Xiao, Mingzhe</au><au>Wang, Cailian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>13</volume><spage>3319</spage><epage>3324</epage><pages>3319-3324</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>Penile squamous cell carcinoma (PSCC) bears poor prognosis due to its rarity and limited treatment options, especially after failure of standard treatments. Effective therapeutic options were desperately needed.
We report a recurrent metastatic PSCC patient with positive programmed death ligand 1 (PD-L1) expression (≥10%) and tumor mutation burden (TMB) of 8.87 (Muts/Mb) who obtained significant response to immunotherapy, with progression-free survival (PFS) exceeding 10 months.
This is the first case presenting remarkable response to immunotherapy in a Chinese PSCC patient. The remarkable response might be associated with PD-L1 expression, indicating that PD-L1 expression could be a promising biomarker for immunotherapy in PSCC. TMB ranking may also contribute to patient selection. However, large clinical trials are needed to validate these notions.</abstract><cop>New Zealand</cop><pub>Dove</pub><pmid>32368090</pmid><doi>10.2147/OTT.S231258</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-6027-3543</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1178-6930 |
ispartof | OncoTargets and therapy, 2020-01, Vol.13, p.3319-3324 |
issn | 1178-6930 1178-6930 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7183339 |
source | Taylor & Francis Open Access; DOVE Medical Press Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central |
subjects | Case Report |
title | Recurrent Metastatic Penile Cancer Patient with Positive PD-L1 Expression Obtained Significant Benefit from Immunotherapy: A Case Report and Literature Review |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T03%3A07%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recurrent%20Metastatic%20Penile%20Cancer%20Patient%20with%20Positive%20PD-L1%20Expression%20Obtained%20Significant%20Benefit%20from%20Immunotherapy:%20A%20Case%20Report%20and%20Literature%20Review&rft.jtitle=OncoTargets%20and%20therapy&rft.au=Su,%20Xiangyu&rft.date=2020-01-01&rft.volume=13&rft.spage=3319&rft.epage=3324&rft.pages=3319-3324&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S231258&rft_dat=%3Cpubmed_cross%3E32368090%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32368090&rfr_iscdi=true |